|Neil Clark, Chief Executive Officer
Mr Clark qualified as an accountant with PwC in Cambridge, UK and worked for over ten years on a variety of national and international assignments in audit, corporate finance and consultancy. In 1997, Mr Clark joined CeNeS Pharmaceuticals plc, a venture capital backed private UK biotech company. Following the successful flotation of CeNeS in 1999, he was appointed CFO. In 2005, he became CEO and led the company through to its sale in 2008. Mr Clark then joined Ergomed in January 2009 and was CFO during its IPO in July 2014 until his move to be full time CEO of PrimeVigilance (Ergomed’s successful drug safety business) in January 2016. Mr Clark is a Fellow of the Institute of Chartered Accountants in England and Wales and has a BSc in Bioscience from the University of Nottingham.
|Dr William Love, Founder and Chief Scientific Officer
Dr Love was a senior scientist at Ciba Geigy/Novartis focused on novel drug delivery technologies and involved in the development of the world’s leading eye-care pharmaceutical, Visudyne. In 1997, Dr Love founded Destiny Pharma and he is the co-inventor of the XF drug platform. Dr Love was a founding member of the BEAM Alliance, an EU SME group focused on promoting antimicrobial drug development. He is an expert advisory board member of Global AMR Innovation Fund, appointed by Professor Dame Sally Davies in October 2016. Dr Love is the named inventor in more than 70 patents. He has experience in drug R&D from discovery and lead identification, through pre-clinical development and into Phase 1/2 clinical development in the UK, EU and US.
|Shaun Claydon, Chief Financial Officer and Company Secretary
Mr Claydon is an accomplished corporate financier and qualified Chartered Accountant with over 16 years’ board level experience, including within the biotechnology sector. He has extensive experience of delivering financial and operating results and from 2015 served as CFO of Creabilis, a venture backed clinical stage specialty pharmaceutical company focused on dermatology treatments, during which he led the $150 million sale of the business to Sienna Biopharmaceuticals. From 2009 to 2014 Mr Claydon was CFO and chief operating officer of Orteq Sports Medicine, a medical device company and world leader in the field of biodegradable polymer technologies. Prior to these positions Mr Claydon held a number of senior financial consultancy and corporate finance roles including at PwC, Evolution Beeson Gregory (now Investec) and HSBC Investment Banking.
|Dr Stephanie Bewick, Chief Business Officer
Dr Bewick has 20 years’ experience in Business Development within public and private biotech companies as well as mid-sized pharma, both in-house and as a consultant. Most recently, she was Vice President, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation, and was also involved in pre-launch activities to support commercialisation of an asset in the US. Throughout her career she has negotiated and closed a range of transactions from early research phase to late clinical stage of development. She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.
|Dr William Rhys-Williams, Vice President, Research Operations
Dr Rhys-Williams is a microbiologist with over 30 years’ experience working in pharmaceutical R&D and has been with Destiny Pharma since 1998. Dr Rhys-Williams has been involved in all the Company’s research programmes from initiation through to clinical stage. He is a named inventor on all the Destiny Pharma patents and has been involved in the drafting, successful prosecution and grant of over 70 patents to date.
|John Graham MSc., Vice President, CMC and Technical Operations
Mr Graham has over 25 years’ experience in pharmaceutical development working within mid-size/large pharma, contract development manufacturing organisations (CDMOs) and biotech companies. Mr Graham joined Destiny plc in 2017 where he has overseen improvements in the production and scale-up of XF-73 API and nasal gel product, as well as playing a key role in the acquisition of NTCD-M3.
|Daniel Hynes, Vice President, Preclinical Development
Mr Hynes has over 18 years drug discovery and development experience working for biotech, contract research and consultancy organisations on projects ranging from lead optimisation to full clinical development. Mr Hynes joined the team at Destiny Pharma as the Director of Preclinical Development in 2018. Since 2006 he has contributed towards nine successful first time in man enabling preclinical development programmes of work and has also contributed towards the development of four successfully registered products in the areas of prostate cancer, advanced gastric cancer, malaria and HAE.